A. Scanni

1.9k total citations · 1 hit paper
48 papers, 1.3k citations indexed

About

A. Scanni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. Scanni has authored 48 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in A. Scanni's work include Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (8 papers) and Lung Cancer Treatments and Mutations (7 papers). A. Scanni is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (8 papers) and Lung Cancer Treatments and Mutations (7 papers). A. Scanni collaborates with scholars based in Italy, Malaysia and United States. A. Scanni's co-authors include M. Tomirotti, Gabriella Farina, Marina Chiara Garassino, Olga Martelli, Roberto Labianca, Calogero Lauricella, Massimo Broggini, Silvia Marsoni, Flavia Longo and Silvio Veronese and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

A. Scanni

46 papers receiving 1.2k citations

Hit Papers

Erlotinib versus docetaxel as second-line treatment of pa... 2013 2026 2017 2021 2013 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
    2013 376 citations Marina Chiara Garassino, Olga Martelli et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Scanni Italy 16 849 600 340 151 129 48 1.3k
Gabriella Farina Italy 24 1.0k 1.2× 785 1.3× 217 0.6× 293 1.9× 219 1.7× 65 1.8k
Nurullah Zengin Türkiye 21 787 0.9× 479 0.8× 175 0.5× 187 1.2× 300 2.3× 160 1.5k
Hikmat Abdel‐Razeq Jordan 17 481 0.6× 195 0.3× 235 0.7× 138 0.9× 118 0.9× 155 1.2k
Hans Starkhammar Sweden 17 1.2k 1.4× 414 0.7× 167 0.5× 469 3.1× 490 3.8× 39 1.9k
David D. Stenehjem United States 18 626 0.7× 402 0.7× 173 0.5× 318 2.1× 239 1.9× 113 1.8k
Jing Yu China 20 883 1.0× 363 0.6× 257 0.8× 501 3.3× 193 1.5× 61 1.7k
Stephen B. Strum United States 21 280 0.3× 1.1k 1.8× 131 0.4× 105 0.7× 409 3.2× 42 1.9k
Waddah B. Al‐Refaie United States 23 917 1.1× 472 0.8× 238 0.7× 58 0.4× 699 5.4× 48 1.5k
Serge Benayoun Canada 12 384 0.5× 1.4k 2.3× 242 0.7× 191 1.3× 379 2.9× 24 2.0k
Margot J. Burnell Canada 12 649 0.8× 254 0.4× 420 1.2× 116 0.8× 100 0.8× 32 1.1k

Countries citing papers authored by A. Scanni

Since Specialization
Citations

This map shows the geographic impact of A. Scanni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Scanni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Scanni more than expected).

Fields of papers citing papers by A. Scanni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Scanni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Scanni. The network helps show where A. Scanni may publish in the future.

Co-authorship network of co-authors of A. Scanni

This figure shows the co-authorship network connecting the top 25 collaborators of A. Scanni. A scholar is included among the top collaborators of A. Scanni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Scanni. A. Scanni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Indini, Alice, C. Aschele, Luigi Cavanna, et al.. (2020). Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey. European Journal of Cancer. 132. 17–23. 73 indexed citations
2.
Garassino, Marina Chiara, Olga Martelli, Massimo Broggini, et al.. (2013). Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. The Lancet Oncology. 14(10). 981–988. 376 indexed citations breakdown →
3.
4.
Mattioli, Rodolfo, Cesare Gridelli, Alfredo Falcone, et al.. (2009). Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. Clinical & Translational Oncology. 11(12). 842–848. 5 indexed citations
5.
Farina, Gabriella, Marina Chiara Garassino, Marcello Gambacorta, et al.. (2007). Response of thymoma to cetuximab. The Lancet Oncology. 8(5). 449–450. 57 indexed citations
6.
7.
Frontini, L., A Ardizzoia, M. Giordano, et al.. (2005). Epirubicine-vinorelbine (EV) intravenous combination followed by oral vinorelbine (VNR) as first-line treatment in advanced breast cancer (ABC) patients: A POLONORD Group study. Journal of Clinical Oncology. 23(16_suppl). 770–770. 5 indexed citations
8.
Ardizzoia, Antonio, Daniele Fagnani, Monica Giordano, et al.. (2004). Second Line Therapy with Weekly Low-dose Docetaxel for Pretreated Non-Small-Cell Lung Carcinoma Patients: A Multicenter Italian Phase II Study. Lung. 182(1). 1–8. 18 indexed citations
9.
Cescon, Matteo, Roberto Assietti, A. Scanni, et al.. (2003). Embryonal rhabdomyosarcoma of the orbit in a liver transplant recipient. Transplant International. 16(6). 437–440. 4 indexed citations
10.
Mustacchi, Giorgio, Rita Ceccherini, Stefano Milani, et al.. (2003). Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Annals of Oncology. 14(3). 414–420. 146 indexed citations
11.
Grazi, Gian Luca, Roberto Assietti, A. Scanni, et al.. (2003). Embryonal rhabdomyosarcoma of the orbit in a liver transplant recipient. Transplant International. 16(6). 437–440. 5 indexed citations
12.
Bossolasco, Patrizia, et al.. (2002). Detection of micrometastatic cells in breast cancer by RT-PCR for the mammaglobin gene. Cancer Detection and Prevention. 26(1). 60–63. 47 indexed citations
13.
Intra, Mattia, Andrea Pisani Ceretti, Mauro Pagani, et al.. (1999). Complications of Subcutaneous Infusion Port in the General Oncology Population. Oncology. 56(2). 97–102. 99 indexed citations
14.
Farina, Gabriella, et al.. (1997). Long Term Toxicity in Adjuvant Treatment with Tamoxifen. Journal of Chemotherapy. 9(4). 300–303. 2 indexed citations
15.
Bajetta, Emilio, Maria Di Bartolomeo, L. Somma, et al.. (1996). Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma. Cancer. 78(10). 2087–2093. 10 indexed citations
16.
17.
Bartolomeo, Maria Di, Emilio Bajetta, Nicoletta Zilembo, et al.. (1993). Treatment of Carcinoid Syndrome with Recombinant Interferon Alpha-2a. Acta Oncologica. 32(2). 235–238. 34 indexed citations
18.
Bajetta, Emilio, Marco Colleoni, Riccardo Rosso, et al.. (1993). Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. European Journal of Cancer. 29(12). 1658–1663. 25 indexed citations
19.
20.
Scanni, A., et al.. (1977). Serum Copper and Ceruloplasmin Levels in Patients with Neoplasias Localized in the Stomach, Large Intestine or Lung. Tumori Journal. 63(2). 175–180. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriella Farina Breakdown of academic impact, for papers by Nurullah Zengin Breakdown of academic impact, for papers by Hikmat Abdel‐Razeq Breakdown of academic impact, for papers by Hans Starkhammar Breakdown of academic impact, for papers by David D. Stenehjem Breakdown of academic impact, for papers by Jing Yu Breakdown of academic impact, for papers by Stephen B. Strum Breakdown of academic impact, for papers by Waddah B. Al‐Refaie Breakdown of academic impact, for papers by Serge Benayoun Breakdown of academic impact, for papers by Margot J. Burnell
Rankless by CCL
2026